– Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of ...

Evidence from a phase 3 trial does not support the addition of Tecentriq to a specific chemotherapy regimen with Avastin for patients with newly diagnosed stage 3 or 4 ovarian cancer. Adding Tecentriq ...

Roche’s Tecentriq appeared on the immuno-oncology scene in May of this year, approved to treat bladder cancer and trailing Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo by more than a year. But ...

Tecentriq (atezolizumab) is a prescription drug that’s used to treat certain cancers. The drug comes as a solution that your doctor will inject. It’s usually given on a cycle every 2, 3, or 4 weeks.

Last year, Roche’s Tecentriq became the first immuno-oncology treatment approved in triple negative breast cancer after it showed it could stall cancer progression in combination with Celgene’s ...

Roche has received the US Food and Drug Administration (FDA) priority review for its supplemental biologics licence application (sBLA) for adjuvant Tecentriq (atezolizumab) and Tecentriq Hybreza ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® ...

– Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone – – ...

– Approval based on the Phase III IMpower110 study showing Tecentriq demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy – “We are ...

Tecentriq combined with BCG did not enhance outcomes for high-risk NMIBC patients compared to BCG alone, with similar event-free survival rates. The ALBAN trial reported higher rates of side effects ...

SOUTH SAN FRANCISCO, Calif., October 20, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III IMvigor011 ...